IHA has partnered with the Huntington Disease Youth Organisation and European Huntington Association to create a global Community Advisory Board, named HD-CAB.
HD-CAB is made up of representatives from HD families around the globe. Members from 20 different countries provide valuable input to researchers, industry representatives, regulators and policy makers and in doing so help ensure that the process and outcome of drug development is WITH the patient and not just FOR the patient.
Further details can be found at here. Countries currently represented by the teams members pictured are Argentina, Australia, Canada, China, Colombia, Egypt, Germany, India, Ireland, The Netherlands, Northern Ireland, Pakistan, Russia, Scotland, South Africa, Spain, Sweden, USA & Venezuela. All members are either at risk, previously at risk, gene positive or living and caring for a loved one with HD. If you would like to know more, please contact email@example.com